The Role of B-Raf Status in Tumor Response to Pazopanib
Author Information
Author(s): Gril Brunilde, Palmieri Diane, Qian Yong, Anwar Talha, Ileva Lilia, Bernardo Marcelino, Choyke Peter, Liewehr David J., Steinberg Seth M., Steeg Patricia S.
Primary Institution: National Cancer Institute, Bethesda, Maryland, United States of America
Hypothesis
Tumor B-Raf status may significantly influence the efficacy of pazopanib in inhibiting tumor growth and angiogenesis.
Conclusion
The study found that tumor B-Raf status is a significant determinant of both tumor growth and angiogenesis when treated with pazopanib.
Supporting Evidence
- Pazopanib significantly inhibited tumor growth in xenografts with exon 11 mutations of B-Raf.
- Tumor B-Raf status correlated with pazopanib's anti-angiogenic activity.
- The study identified a unique pattern of pazopanib activity relative to B-Raf signaling.
Takeaway
This study shows that the type of B-Raf gene in tumors can change how well a cancer drug called pazopanib works.
Methodology
The study used a panel of seven human breast cancer and melanoma cell lines implanted in mice to analyze tumor growth and angiogenesis in response to pazopanib treatment.
Potential Biases
Potential bias due to the selection of specific cell lines that may not fully represent the diversity of tumors.
Limitations
The study primarily focused on a limited number of cell lines and may not represent all tumor types.
Participant Demographics
The study involved athymic nude mice for in vivo experiments.
Statistical Information
P-Value
p=0.009
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website